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Abstract
Background: KiSS-1 was identified as a metastasis-suppressing gene in melanoma cells. The KiSS-
1 gene product (metastin) was isolated from human placenta as the ligand of GPR54, a G-protein-
coupled receptor. The role of metastin and GPR54 in tumor progression is not fully understood.
Methods: We investigated the clinical significance of metastin and GPR54 expression in pancreatic
cancer. We evaluated immunohistochemical expression of metastin and GPR54 in pancreatic ductal
adenocarcinoma tissues obtained from 53 consecutive patients who underwent resection between
July 2003 and May 2007 at Kyoto University Hospital. In 23 consecutive patients, the plasma
metastin level was measured before surgery by enzyme immunoassay.
Results: Strong immunohistochemical expression of metastin was detected in 13 tumors (24.5%),
while strong expression of GPR54 was detected in 30 tumors (56.6%). Tumors that were negative
for both metastin and GPR54 expression were significantly larger than tumors that were positive
for either metastin or GPR54 (p = 0.047). Recurrence was less frequent in patients who had
metastin-positive tumors compared with those who had metastin-negative tumors (38.5% versus
70.0%, p = 0.04). Strong expression of metastin and GPR54 was significantly correlated with longer
survival (p = 0.02). Metastin expression by pancreatic cancer was an independent prognostic factor
for longer survival (hazard ratio, 2.1; 95% confidence interval, 1.1–4.7; p = 0.03), and the patients
with a high plasma metastin level (n = 6) did not die after surgical resection.
Conclusion: Strong expression of metastin and GPR54 by pancreatic cancer is associated with
longer survival. Metastin expression is an independent prognostic factor for the survival of
pancreatic cancer patients. The plasma metastin level could become a noninvasive prognostic factor
for the assessment of pancreatic cancer.
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Background
Pancreatic cancer remains a lethal disease and is the
fourth to fifth leading cause of cancer-related death in the
Western world, despite a significant reduction of the post-
operative morbidity and mortality associated with pancre-
atectomy[1,2]. While surgical resection represents the
only definitive option for cure of this disease and com-
plete tumor resection is associated with longer survival,
only 10% to 15% of patients have resectable disease[3,4].
Most patients with pancreatic cancer have locally
advanced tumors, metastases, or both at the time of diag-
nosis. In addition, tumors frequently recur, even after
margin-free curative resection, and most patients with
recurrence have metastasis, which is often fatal. To
improve the survival of patients with pancreatic cancer,
we need a new strategy for the treatment of advanced dis-
ease that is unsuitable for surgical resection.
Metastasis is a multistep process in which tumor cells
migrate through the stroma and invade a vessel, after
which the cells are transported through the circulation to
re-invade and proliferate at a distant site. Dozens of regu-
lators influence each step of the metastatic cascade[5,6].
In 1996, KiSS-1 was identified as a human metastasis-sup-
pressing gene in melanoma cells[7] and breast cancer
cells[8]. Then, the KiSS-1 gene product was isolated from
human placenta as the endogenous ligand of an orphan
G-protein-coupled receptor known as GPR54[9],
AXOR12[10], or hOT7T175[11]. KiSS-1 encodes a 145-
amino acid peptide which is further processed to a C-ter-
minally amidated peptide with 54 amino acids called
metastin[11] or kisspeptin-54, as well as to peptides with
14 amino acids (kisspeptin-14) and 13 amino acids
(kisspeptin-13)[9].
The bioactive sequence of the KiSS-1 gene product is the
C-terminal 10 amino acids, metastin (45–54) (metastin-
10 or kisspeptin-10)[12]. Metastin was shown to inhibit
the chemotaxis and invasion of GPR54-transfected Chi-
nese hamster ovary cells in vitro, while it inhibited the pul-
monary metastasis of GPR54-transfected melanoma cells
in vivo[11]. The prognostic relevance of KiSS-1 has been
demonstrated for some solid tumors [13-21].
In addition to the inhibition of tumor metastasis, KiSS-1
shows neuroendocrine activity and has a role in the gona-
dotropin-releasing hormone cascade, puberty, placenta-
tion, and reproduction, as shown by recent
studies[22,23]. In normal tissues, the highest level of
KiSS-1 mRNA expression has been detected in the pla-
centa, with moderate to weak expression in the central
nervous system, testis, liver, pancreas, and intes-
tine[7,10,11]. In the case of GPR54 mRNA, high levels of
expression are found in the placenta, pancreas, and cen-
tral nervous system [9-11].
We previously found that expression of KiSS-1 mRNA was
lower and expression of GPR54 mRNA was higher in pan-
creatic cancer tissue compared with normal pancreatic tis-
sue[24]. However, the clinical significance of KiSS-1 and
GPR54 expression by pancreatic cancer remains unclear.
We hypothesized high levels of KiSS-1 and GPR54 expres-
sion could be associated with better survival of pancreatic
cancer patients. Therefore, we investigated immunohisto-
chemical expression of the KiSS-1 gene product (metas-
tin) and that of GPR54 in pancreatic cancer tissues
obtained by surgical resection. We also measured plasma
metastin levels in pancreatic cancer patients by using an
enzyme immunoassay (EIA) that we previously estab-
lished[25] and evaluated the clinical applicability of these
two parameters.
Methods
Patients
A total of 53 consecutive patients with pancreatic cancer
who underwent surgical resection between July 2003 and
May 2007 at Kyoto University Hospital were studied. The
diagnosis of ductal adenocarcinoma of the pancreas was
confirmed histologically by at least two pathologists who
examined the resected specimens. None of the patients
received preoperative chemotherapy or radiation therapy,
and all patients gave written informed consent to partici-
pation in the study. Follow-up information was obtained
from the medical records or by direct contact with patients
or their referring physicians.
We evaluated the following clinicopathological character-
istics according to the sixth edition of the TNM classifica-
tion of the international union against cancer
(UICC)[26]: tumor location, tumor size, tumor extent
(pT), lymph node metastasis (pN), pStage, histopatholog-
ical grade (G), lymphatic invasion, venous invasion,
perineural invasion, and residual tumor (R).
Immunohistochemical staining for metastin and GPR54
Immunohistochemical staining of resected pancreatic tis-
sues was done in 53 patients with ductal adenocarcinoma
of the pancreas. We chose sections that contained cancer
tissue and adjacent non-cancerous tissue in the same sec-
tion.
Paraffin-embedded tissue blocks were cut into 4 μm sec-
tions, dried overnight at 37°C, and then deparaffinized
with xylene and rehydrated in a graded ethanol series. Sec-
tions were treated with Dako target retrieval solution
(Dako, Carpinteria, CA, USA) before antigen retrieval was
done by heating at 95°C for 40 min. Then the sections
were cooled to room temperature, and were treated with
dilute hydrogen peroxide to block endogenous peroxidase
activity. Nonspecific binding was minimized by incuba-
tion with Dako protein block (Dako) for 30 min. RabbitJournal of Experimental & Clinical Cancer Research 2009, 28:9 http://www.jeccr.com/content/28/1/9
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anti-human polyclonal antibodies for metastin (1–54)-
Amide (catalogue number: H-048-59, Phoenix Pharma-
ceuticals, Inc., Burlingame, CA, USA) and GPR54 (375–
398) (catalogue number: H-048-61, Phoenix Pharmaceu-
ticals) were applied overnight at 4°C at a dilution of
1:400. On the next day, sections were incubated for 1 hr
at room temperature with anti-rabbit IgG conjugated to a
horseradish peroxidase (HRP) -labelled polymer (Dako
Envision™ + System, Dako), treated with 3,3'-diami-
nobenzidine tetrahydrochloride (DAB), and counter-
stained with Mayer's hematoxylin. As a positive control,
human placental tissue was stained with the anti-metastin
and anti-GPR54 antibodies (Figure 1A, 1B). For negative
control slides, the primary antibody was substituted with
irrelevant rabbit serum.
Assessment of metastin and GPR54 expression
Five fields (at a × 400 magnification) were randomly cho-
sen to evaluate staining. The intensity of staining in cancer
tissues was graded according to a 3-point scale as follows:
0 was weak; 1 was mild (the same staining intensity as that
of non-cancerous pancreatic ducts as an internal control
on each slide); and 2 was strong. The percentage of tumor
cells showing each staining intensity was estimated to cal-
culate an intensity score ([0 × %weak] + [1 × %mild] + [2
× %strong]) that could range from 0 to 200. A score ≥ 100
was defined as positive staining and a score <100 was
defined as negative staining.
Then we compared clinicopathological characteristics
between patients with positive and negative staining for
metastin and GPR54.
Blood sampling and EIA for plasma metastin
Plasma levels of metastin were measured by EIA, as
described previously[25], in 23 consecutive patients who
underwent resection between July 2006 and May 2007.
A blood sample was collected in the morning before sur-
gery, placed in a chilled tube containing aprotinin (500
KIU/ml) and EDTA (1.2 mg/ml), and immediately centri-
fuged. The plasma thus obtained was diluted five-fold
with 4% acetic acid (pH 4.0), and loaded onto a column
with a C18 reversed-phase cartridge (Sep-Pak C18, Milli-
pore, Milford, MA, USA). After washing with 4% acetic
acid, peptides were eluted with 70% acetonitrile in 0.5%
acetic acid (pH 4.0). The eluted samples were concen-
trated by spin-vacuum evaporation, lyophilized, and
stored at -40°C until assay.
EIA was performed by the delayed-addition method with
separation of bound and free antigens on anti-rabbit IgG-
coated immunoplates. Human metastin (45–54) was
conjugated with β-D-galactosidase using N-(ε-maleimido-
caproyloxy)-succinimide, as reported previously[27]. The
EIA was sensitive and specific for all bioactive KiSS-1 gene
products (metastin, kisspeptin-14, and kisspeptin-
13)[25].
The third quartile value was set as a cut-off for the plasma
metastin level. We evaluated the association between the
plasma level of metastin and metastin immunoreactivity
in resected pancreatic cancer tissues, and also the associa-
tions between plasma metastin and the clinicopathologi-
cal characteristics of the patients.
Statistical analysis
Continuous variables are presented as the mean ± stand-
ard deviation or as the median and range. Comparison of
the groups was done with the Mann-Whitney U test, while
categorical variables were compared by the χ2 test. Corre-
lations between metastin and GPR54 immunoreactivity
were investigated by calculation of Pearson's correlation
coefficient (r) values and scatter plots with a linear regres-
sion line were drawn. An r value of 0–0.19 was defined as
a very weak correlation, while 0.2–0.39 was weak, 0.40–
0.59 was moderate, 0.6–0.79 was strong, and 0.8–1 was
very strong. Overall survival curves were drawn by the
Kaplan-Meier method, and were compared by the log-
rank test. Prognostic factors for survival were examined by
univariate and multivariate analyses using Cox's propor-
tional hazards model. For all analyses, p < 0.05 was con-
sidered to be statistically significant.
Results
Demographic and clinicopathological characteristics
There were 25 men (47.2%) and 28 women (52.8%) with
a mean age at diagnosis of 65.6 years (median age: 68
years; range: 32 – 86 years). The tumor was located in the
head of the pancreas in 38 patients (71.7%), while it was
found in the distal pancreas in 15 patients (28.3%). Pan-
creatoduodenectomy was performed in 36 patients
(67.9%), while distal pancreatectomy was performed in
13 patients (24.5%), and total pancreatectomy in 4
patients (7.5%). On histopathological examination, one
patient (1.9%) had pStage IA disease, three patients
(5.7%) had pStage IB, 16 patients (30.2%) had pStage IIA,
29 patients (54.7%) had pStage IIB, and four patients
(7.5%) had pStage IV.
Twenty-nine patients received adjuvant chemotherapy,
which consisted of S-1 (n= 18), gemcitabine (n = 8), 5-
fluorouracil (n = 2), and tegafur-uracil (n = 1). This was
excluded from statistical analysis because of variations in
the duration and type of chemotherapy.
Immunostaining for metastin and GPR54
Pancreatic cancer tissues showed heterogenous immuno-
reactivity for metastin and GPR54 (Figure 1). Acinar cells
and islet cells did not exhibit any immunoreactivity, whileJournal of Experimental & Clinical Cancer Research 2009, 28:9 http://www.jeccr.com/content/28/1/9
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Immunohistochemical staining of non-cancerous pancreatic tissues and pancreatic cancer tissues Figure 1
Immunohistochemical staining of non-cancerous pancreatic tissues and pancreatic cancer tissues. (A, B); Immu-
nohistochemical staining of human placental tissues as a positive control. Tissues were stained with anti-metastin (A) and anti-
GPR54 antibody (B). (Original magnification, × 200). (C, D); Non-cancerous and cancerous tissues were stained with anti-
metastin and anti-GPR54 antibody. (Original magnification, × 400). Weak positivity of non-cancerous ductal cells for metastin 
(C) and GPR54 (D). (E, F); Pancreatic cancer tissues were stained with anti-metastin and anti-GPR54 antibody. Heterogeneous 
strong positive immunostaining of carcinoma cells for metastin (E) and GPR54 (F) are shown.Journal of Experimental & Clinical Cancer Research 2009, 28:9 http://www.jeccr.com/content/28/1/9
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metastin and GPR54 were both weak or mildly positive in
the cytoplasm of normal pancreatic ductal cells.
The mean intensity score for metastin was 72.1 ± 54.9 (n
= 53) and that for GPR54 was 99.9 ± 55.1 (n = 53) (Figure
2).
Positive metastin staining was detected in 13 tumors
(24.5%), while GPR54 was positive in 30 tumors
(56.6%). Immunoreactivity for metastin and GPR54
showed a strong positive correlation (r = 0.62, p < 0.001;
Fig. 3).
Demographic and clinicopathological characteristics
showed no significant differences between patients whose
tumors were positive or negative for metastin (Table 1),
and the outcome was similar for GPR54 (Table 2). How-
ever, tumors that were negative for both metastin and
GPR54 showed a significantly larger size than tumors pos-
itive for metastin and/or GPR54 (median of 2.5 cm and
range of 0.8–5.0 cm versus median of 3.0 cm and range of
1.5–6.5 cm, p = 0.047).
Recurrence and survival
The median postoperative follow-up period was 18.5
months (range: 2.6–59.2 months). There were no opera-
tive deaths in this series. During the follow-up period, 33
patients (62.3%) showed recurrence and 25 patients
(47.2%) died of their cancer. Recurrence was detected in
the liver (n = 15), local region (n = 9), peritoneum (n = 9),
lymph nodes (n = 5), lungs (n = 1), and bone (n = 1),
while it was at an unknown location in 1 patient (elevated
tumor marker). No patient died of any other disease or
cause.
The recurrence rate was significantly lower in the patients
whose tumors were positive for metastin than in those
with negative tumors (38.5% versus 70.0%, p = 0.04)
(Table 3). There were no significant differences of the
recurrence rate at each site between the patients with
metastin-positive and -negative tumors (Table 3), and the
same was found for GPR54 (Table 4).
The overall survival of patients whose tumors were posi-
tive for metastin was significantly longer than that of
patients with negative tumors (p = 0.02) (Figure 4). Simi-
larly, the overall survival of patients with tumors that were
positive for GPR54 was significantly longer than that of
patients with negative tumors (p = 0.02) (Figure 5).
Prognostic factors according to multivariate analysis
Univariate and multivariate analysis were performed to
identify parameters associated with overall survival
according to the Cox proportional hazards model. The
univariate analysis revealed the following five factors to be
associated with survival: perineural invasion, pStage,
residual tumor, metastin expression, and GPR54 expres-
sion. In the multivariate analysis, as well as the UICC
pStage (I + II versus IV), overexpression of metastin was an
independent prognostic factor for better survival (hazard
ratio, 2.08; 95% confidence interval, 1.05–4.71; p = 0.03)
(Table 5).
Expression of metastin and GPR54 in pancreatic cancer tis- sues Figure 2
Expression of metastin and GPR54 in pancreatic can-
cer tissues. Immunoreactivity for metastin and GPR54 in 
resected pancreatic cancer tissues (n = 53) shown as the 
intensity score of each patient. The mean metastin intensity 
score was 72.1 ± 54.9 and that for GPR54 was 99.9 ± 55.1. 
The horizontal bar indicates the mean ± SD.
Correlation between metastin and GPR54 expression in pan- creatic cancer tissues Figure 3
Correlation between metastin and GPR54 expres-
sion in pancreatic cancer tissues. Scatter plot showing 
the correlation between immunoreactivity for metastin and 
GPR54. A strong correlation was found (r = 0.62, p < 0.001).Journal of Experimental & Clinical Cancer Research 2009, 28:9 http://www.jeccr.com/content/28/1/9
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Plasma metastin level
The mean plasma level of metastin before surgery was
22.7 ± 17.2 fmol/ml (median, 21.5 fmol/ml; range, 4.0–
58.9 fmol/ml). Plasma metastin levels and the intensity
score for metastin immunoreactivity in resected tissues
showed a weak correlation (r = 0.23, p = 0.30). When we
used the third quartile plasma metastin level (28.0 fmol/
ml) as a cut-off value, there were no significant differences
of demographics and clinicopathological characteristics
between patients with a high (n = 6) or low (n = 17)
plasma metastin level.
Overall survival curves of the patients with high and low
plasma metastin levels are shown in Fig. 6. The median
postoperative follow-up period was 14.8 months (range:
2.6–22.1 months, n = 23). While survival showed no sig-
nificant difference between the two groups (p = 0.14), no
patient with a high plasma metastin levels died after sur-
gery (Figure 6).
Discussion
In this study, we investigated the clinical significance of
immunohistochemical metastin and GPR54 expression in
resected pancreatic cancer tissues. We found that strong
expression of metastin or GPR54 was associated with bet-
ter survival, and metastin expression was an independent
prognostic factor for longer survival of pancreatic cancer
patients. Our results indicate that the metastin/GPR54 sig-
naling system acts to suppress the growth of pancreatic
cancer.
Recently, the prognostic relevance of KiSS-1 and GPR54
has been investigated in some solid tumors [13-21]. Most
of these studies have shown that the KiSS-1/GPR54 system
is negatively correlated with tumor progression. KiSS-1
has been demonstrated to act as a suppressor in
melanoma[13], thyroid cancer[14], bladder cancer[16],
gastric cancer[17], esophageal cancer[18], and ovarian
cancer[20].
Table 1: Comparison of the patients with pancreatic cancer who had positive immunostaining for metastin and those negative.
Characteristics Positive for metastin Negative for metastin P value
(n = 13) (n = 40)
Age 68.8 ± 7.2 (71, 56–78) 64.5 ± 10.5 (65.5, 32–86) 0.19
Gender
Male 6 19 0.93
Female 7 21
Location of tumor
Pancreas head 8 30 0.35
Pancreas body-tail 5 10
Size of tumor, cm 2.5 ± 0.9 (2.5, 1.2–4.5) 3.0 ± 1.2 (2.8, 0.8–6.5) 0.34
Histopathological grading
G1 5 9 0.26
G2-4 8 31
pT
pT1, pT2 2 6 0.97
pT3 11 34
pN
pN0 6 15 0.58
pN1 7 25
Lymphatic invasion
Positive 7 24 0.70
Negative 6 16
Venous invasion
Positive 7 23 0.82
Negative 6 17
Perineural invasion
Positive 6 22 0.58
Negative 7 18
pStage
I, II 13 36 0.24
IV 0 4
Residual tumor
R0 11 28 0.30
R1 2 12
Median and range are shown in parentheses.Journal of Experimental & Clinical Cancer Research 2009, 28:9 http://www.jeccr.com/content/28/1/9
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For example, Shirasaki et al[13] showed that downregula-
tion of KiSS-1  is important for the progression of
melanoma in vivo. Ringel et al[14] showed that KiSS-1
and GPR54 mRNA were overexpressed in papillary thy-
roid cancer compared with follicular cancer. In bladder
cancer, loss of KiSS-1 expression is related to tumor pro-
gression[16]. In gastric cancer, lower expression of KiSS-1
mRNA is associated with venous invasion, distant metas-
tasis, and tumor recurrence[17]. Furthermore, KiSS-1 is an
independent prognostic marker for gastric cancer accord-
ing to multivariate analysis [17]. Ikeguchi et al. [18]
observed that loss of KiSS-1  mRNA, GPR54  mRNA, or
Table 2: Comparison of the patients with pancreatic cancer who had positive immunostaining for GPR54 and those negative.
Characteristics Positive for GPR54 Negative for GPR54 P value
(n = 30) (n = 23)
Age 66.1 ± 8.7 (65.5, 49–86) 64.9 ± 11.5 (68.0, 32–80) 0.99
Gender
Male 12 13 0.23
Female 18 10
Location of tumor
Pancreas head 21 17 0.75
Pancreas body-tail 9 6
Size of tumor, cm 2.7 ± 1.0 (2.5, 0.8–5.0) 3.1 ± 1.2 (3.0, 1.2–6.5) 0.13
Histolopathological grading
G1 10 4 0.19
G2-4 20 19
pT
pT1, pT2 6 2 0.25
pT3 24 21
pN
pN0 13 8 0.53
pN1 17 15
Lymphatic invasion
Positive 18 13 0.80
Negative 12 10
Venous invasion
Positive 18 12 0.57
Negative 12 11
Perineural invasion
Positive 15 13 0.64
Negative 15 10
pStage
I, II 29 20 0.18
IV 1 3
Residual tumor
R0 24 15 0.23
R1 6 8
Median and range are shown in parentheses.
Table 3: The rate and site of recurrence after resection of pancreatic cancer in relation to metastin expression.
Metastin expression Positive (n = 13) Metastin expression Negative (n = 40) P value
Recurrence, n (%) 5 (38.5%) 28 (70.0%) 0.04
Site of recurrence
Liver, n (%) 4 (30.8%) 11 (27.5%) 0.82
Local, n (%) 2 (15.4%) 7 (17.5%) 0.86
Peritoneum, n (%) 1 (7.7%) 8 (20.0%) 0.30
Lymph nodes, n (%) 1 (7.7%) 4 (10.0%) 0.80
Lungs, n (%) 0 1 (2.5%) 0.56
Bone, n (%) 0 1 (2.5%) 0.56
Unknown*, n (%) 0 1 (2.5%) 0.56
* Confirmed by elevated tumor marker during follow-upJournal of Experimental & Clinical Cancer Research 2009, 28:9 http://www.jeccr.com/content/28/1/9
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both in esophageal squamous cell carcinoma was a signif-
icant predictor of lymph node metastasis. Finally, the sur-
vival of ovarian cancer patients with low GPR54 mRNA
expression is significantly worse than that of those with
high expression[20].
On the other hand, studies in patients with breast can-
cer[19] and hepatocellular carcinoma (HCC) [15,21]
have yielded opposite results, with a positive association
between increased KiSS-1 levels and disease progression.
Martin et al. [19] found that KiSS-1 mRNA expression was
increased in aggressive breast cancer. Ikeguchi et al. [15]
reported that overexpression of KiSS-1 and GPR54 was
correlated with the progression of HCC. Schmid et al. [21]
performed an immunohistochemical study and con-
cluded that high KiSS-1 expression was an independent
prognostic factor for shorter survival of patients with
HCC.
The mechanism by which the KiSS-1/GPR54 system regu-
lates tumor progression still remains unclear, although
various studies have revealed the downstream signaling
pathways activated by KiSS-1 gene product. This might
indicate that a complex signaling network exists with
diverse physiological responses [23,28].
Stafford et al. [29] found that binding of KiSS-1 peptide to
the receptor leads to activation of G-protein-activated
phospholipase C, which suggested a direct relation of
KiSS-1 to the Gαq-mediated phospholipase C-Ca2+ signal-
ing pathway. In addition, activation of GPR54 has been
shown to cause an increase of intracellular calcium [9-11],
Table 4: The rate and site of recurrence after resection of pancreatic cancer in relation to GPR54 expression.
GPR54 expression Positive (n = 30) GPR54 expression Negative (n = 23) P value
Recurrence, n (%) 17 (56.7%) 16 (69.6%) 0.34
Site of recurrence
Liver, n (%) 8 (26.7%) 7 (30.4%) 0.76
Local, n (%) 6 (20.0%) 3 (13.0%) 0.50
Peritoneum, n (%) 5 (16.7%) 4 (17.4%) 0.95
Lymph nodes, n (%) 2 (6.7%) 3 (13.0%) 0.43
Lungs, n (%) 1 (3.3%) 0 0.38
Bone, n (%) 0 1 (4.3%) 0.25
Unknown*, n (%) 0 1 (4.3%) 0.25
* Confirmed by elevated tumor marker during follow-up
Impact of metastin expression on survival time of pancreatic  cancer patients Figure 4
Impact of metastin expression on survival time of 
pancreatic cancer patients. Overall survival of patients 
whose tumors were positive (n = 13) or negative (n = 40) for 
metastin immunostaining. The survival of patients with posi-
tive tumors was significantly longer than that of patients with 
negative tumors (p = 0.02).
Impact of GPR54 expression on survival time of pancreatic  cancer patients Figure 5
Impact of GPR54 expression on survival time of pan-
creatic cancer patients. Overall survival of patients whose 
tumors were positive (n = 30) or negative (n = 23) for 
GPR54 immunostaining. The survival of patients with tumors 
positive for GPR54 was significantly longer than that of those 
with negative tumors (p = 0.02).Journal of Experimental & Clinical Cancer Research 2009, 28:9 http://www.jeccr.com/content/28/1/9
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arachidonic acid release [9], activation of mitogen-acti-
vated protein kinases (MAPKs), and activation of extracel-
lular signal-regulated kinase (ERK) 1/2[9,14]. We have
observed that exogenous metastin reduces migration of
pancreatic cancer cells, while it induces the activation of
ERK1 and p38[24]. Furthermore, the KiSS-1 product was
shown to repress 92-kDa type 4 collagenase and matrix
metalloproteinase (MMP)-9 expression by decreasing the
binding of NF-κB to the promoter [30]. Bilban et al. [31]
also found downregulation of MMP-2 activity by the KiSS-
1 gene product in human trophoblasts, which implies an
association between the tumor suppressor role of KiSS-1
suggested in this study and our previous report that acti-
vation of MMP-2 has a significant role in invasion and
metastasis of pancreatic cancer[32].
KiSS-1 has also been shown to influence cell adhesion by
forming focal adhesions through phosphorylation of
focal adhesion kinase and paxillin [11], and an associa-
tion between loss of KiSS-1 expression and E-cadherin
expression was reported in bladder cancer [16].
In our series, there were no significant differences of clin-
icopathological characteristics between the patients
whose tumors showed positive and negative metastin
immunostaining, and the result was similar for GPR54.
On the other hand, patients whose tumors showed nega-
tive immunoreactivity for both metastin and GPR54 had
significantly larger tumors than those with lesions posi-
tive for either molecule. In addition, recurrence was more
frequent in the patients with metastin-negative tumors
than in those with metastin-positive tumors. These results
suggest that pancreatic cancer loses metastin and GPR54
expression along with its progression. The KiSS-1 gene is
mapped to chromosome 1q32-q41 [33] and KiSS-1
expression is regulated by genes located on chromosome
6 within the region 6q16.3-q23 [13,28]. These findings
are consistent with the fact that loss of 6q, 8p, 9p, 12q,
17p, and 18q is frequently observed in pancreatic can-
cer[34,35].
Finally, we measured the plasma metastin level in 23 of
our patients with pancreatic cancer. We previously found
Table 5: Univariate and Multivariate analyses of factors associated with survival after resection in patients with pancreatic cancer.
Univariate analysis Multivariate analysis
Characteristics Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (continuous variables) 1.01 (0.97–1.1) 0.50 1.03 (0.97–1.1) 0.29
Gender (male versus female) 1.09 (0.73–1.6) 0.66 1.16 (0.73–1.9) 0.52
Location of tumor (head versus body-tail) 1.08 (0.72–1.7) 0.72 0.71 (0.40–1.3) 0.25
Size of tumor (continuous variables) 1.01 (0.97–1.0) 0.63 1.01 (0.96–1.1) 0.69
Histopathological grading (G1 versus G2-4) 1.05 (0.70–1.7) 0.80 0.92 (0.49–1.8) 0.79
pT (pT1, pT2 versus pT3) 1.62 (0.88–4.0) 0.14 2.07 (0.86–6.7) 0.11
pN (pN0 versus pN1) 1.27 (0.85–2.0) 0.25 1.01 (0.58–1.8) 0.97
Lymphatic invasion (positive versus negative) 1.20 (0.80–1.8) 0.33 0.97 (0.54–1.7) 0.92
Venous invasion (positive versus negative) 1.01 (0.68–1.5) 0.95 0.91 (0.52–1.6) 0.73
Perineural invasion (positive versus negative) 1.57 (1.1–2.4) 0.03 1.47 (0.85–2.7) 0.17
pStage (I, II versus IV) 3.16 (1.6–5.8) 0.002 2.70 (1.1–6.8) 0.03
Residual tumor (R0 versus R1) 1.61 (1.0–2.5) 0.03 1.60 (0.91–2.9) 0.10
Metastin expression (positive versus negative) 1.93 (1.1–4.0) 0.01 2.08 (1.1–4.7) 0.03
GPR54 expression (positive versus negative) 1.62 (1.1–2.5) 0.02 1.22 (0.74–2.0) 0.43
Impact of plasma metastin levels on survival time of pancre- atic cancer patients Figure 6
Impact of plasma metastin levels on survival time of 
pancreatic cancer patients. Overall survival of patients 
with high (n = 6) and low (n = 17) plasma metastin levels. 
There was no significant difference between the two groups 
(p = 0.14), but no patient with a high plasma metastin level 
died after surgery.Journal of Experimental & Clinical Cancer Research 2009, 28:9 http://www.jeccr.com/content/28/1/9
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that the plasma metastin level of patients with pancreatic
cancer is significantly higher than that of age- and gender-
matched healthy volunteers (unpublished data), so we
considered that there was potential to use plasma metas-
tin as a novel tumor marker. In the present series, there
was no significant difference of survival between the
patients with high and low plasma metastin levels, but no
patient with a high plasma metastin level died after sur-
gery. Since the number of patients and the follow-up
period are insufficient, more data and further investiga-
tion will be needed to clarify the value of measuring
plasma metastin.
In this study, the plasma metastin level and metastin
immunoreactivity in resected tumor tissues showed a
weak correlation. It would be clinically useful if plasma
metastin levels had prognostic significance because
metastin expression in resected tumor tissues was shown
to be a prognostic factor in this study.
Conclusion
In conclusion, expression of metastin and GPR54 was
associated with better survival of patients with pancreatic
cancer. Metastin expression by cancer tissue was an inde-
pendent prognostic factor for better survival. Further-
more, the serum metastin level could become a non-
invasive prognostic tool for patients with pancreatic can-
cer.
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